Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.54 |
| ▸ | PPARD | Q03181 | 8/20 | 0.54 |
| ▸ | PPARA | Q07869 | 8/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811081 | 0.93 | PPARA (0.61) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL5562121 | 0.93 | PPARG (0.55) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL4415663 | 0.92 | PPARG (0.54) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1807883 | 0.91 | PPARG (0.53) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1809939 | 0.91 | PPARG (0.55) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1809992 | 0.90 | PPARG (0.59) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1811442 | 0.90 | PPARG (0.57) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1812285 | 0.90 | PPARG (0.54) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1809694 | 0.90 | NR1H2 (0.49) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1810681 | 0.89 | PPARG (0.53) | PPARGPPARDPPARANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4682192-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | claimed |
| EP-1756096-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | claimed |
| US-7173048-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | claimed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | claimed |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | US | claimed |
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-7485652-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | DEHMLOW HENRIETTA | 2007-05-03 | — | — | US | disclosed |
| EP-1756096-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7173048-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | PPARG 30/4885PPARD 29/4885PPARA 33/4885 |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | PPARG 30/4885PPARD 29/4885PPARA 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.